


Product Data Sheet

I-CBP 112

Cat. No.:	A4490
CAS No.:	1640282-31-0
Formula:	C ₂₇ H ₃₆ N ₂ O ₅
M.Wt:	468.59
Synonyms:	
Target:	Chromatin/Epigenetics
Pathway:	Bromodomain
Storage:	Store at 4°C



Solvent & Solubility

≥49.6 mg/mL in DMSO; ≥47.1 mg/mL in EtOH; insoluble in H₂O

In Vitro

Preparing Stock Solutions	Solvent Concentration	Mass		
		1mg	5mg	10mg
	1 mM	2.1341 mL	10.6703 mL	21.3406 mL
	5 mM	0.4268 mL	2.1341 mL	4.2681 mL
	10 mM	0.2134 mL	1.0670 mL	2.1341 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

CBP/EP300 bromodomain inhibitor

IC₅₀ & Target

~170 nM (CREBBP), 625 nM (EP300)

In Vitro

Cell Viability Assay

Cell Line:	Immortalized murine bone marrow cells, human leukemic cells
Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	0.1-10 μM, 48 h or 72 h
Applications:	In immortalized murine bone marrow cells, I-CBP112 (0.1-10 μM, 48 h or 72 h)

impaired clonogenic growth of immortalized murine bone marrow cells. In immortalized murine bone marrow cells, I-CBP112 (10 μ M, 72 h) showed significant cytotoxicity. I-CBP112 significantly reduced clonogenic growth of MLL-CBP immortalized cells in MC cells. I-CBP112 (3 μ M, 3 days) impaired the clonogenic growth of human leukemic cells and sensitized them to BET inhibition and doxorubicin.

Animal experiment

Animal models:	Mice transplanted with bone marrow retrovirally expressing fusion oncogenes
Dosage form:	5 μ M, 3 days
Applications:	I-CBP112 pre-treatment of MLL-AF9+ murine AML blasts reduced the number of LICs and delayed induction of the disease upon transplantation into irradiated recipients.
Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

In Vivo

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Picaud S, Fedorov O, Thanasopoulou A, et al. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy[J]. Cancer research, 2015, 75(23): 5106-5119.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APEX BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

